GMDA - Gamida: Israeli Company Developing Enhanced HSCT Doesn't Convince
Gamida (GMDA) is a small, pivotal stage Israeli company developing Nicotinamide-enhanced cell therapies targeting a number of cancers. The clinical proposition is interesting: The company is using its technology to improve the prospects of hematopoietic stem cell transfer or HSCT, which is curative for a number of cancers, but which has limitations. These are basically four - lack of rapid availability due to type mismatch, inefficient engraftment, delayed onset of immune activation leading to infections, and host rejection leading to graft versus host disease or GvHD.
The company claims that its nicotinamide technology